Agios Pharmaceuticals, Inc. (LON:0HB0)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.18B -23.0% |
| Revenue (ttm) | 33.32M +36.3% |
| Net Income | -298.52M |
| EPS | -5.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3 |
| Average Volume | 204 |
| Open | 28.60 |
| Previous Close | 26.30 |
| Day's Range | 27.65 - 28.60 |
| 52-Week Range | 22.40 - 45.81 |
| Beta | 0.89 |
| RSI | 41.75 |
| Earnings Date | Feb 12, 2026 |
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of a... [Read more]
News
Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET
CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients wit...
Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Agios Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Agios Pharmaceuticals, Inc. (AGIO) 44th Annual J.P.
Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-14. The following slide deck was published by Agios Pharmaceuticals, Inc.
Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth
AQVESME™ (mitapivat) U.S. commercial launch in thalassemia underway following December 2025 FDA approval Pre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of ...
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) to $25 | AGIO Stock News
JP Morgan Raises Price Target for Agios Pharmaceuticals (AGIO) to $25 | AGIO Stock News
Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . HC Wainwr...
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price Target | AGIO Stock News
AGIO: Analyst Andrew Berens Raises Agios Pharmaceuticals Price Target | AGIO Stock News
B of A Securities Maintains Agios Pharmaceuticals (AGIO) Buy Recommendation
Fintel reports that on December 24, 2025, B of A Securities maintained coverage of Agios Pharmaceuticals (NasdaqGS:AGIO) with a Buy recommendation. Analyst Price Forecast Suggests 12.72% Upside
Truist Securities Raises Price Target for AGIO to $38.00 | AGIO Stock News
Truist Securities Raises Price Target for AGIO to $38.00 | AGIO Stock News
Agios Pharma Stock: A Buy After FDA Approves Aqvesme
Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future catalysts. Click here to read.
Here's Why Shares in Agios Pharmaceuticals Popped Today
The company received FDA approval for its leading drug, and investors were pleased with the update from management.
AGIO Rises Nearly 20% On FDA Approval Of AQVESME For Thalassemia Anemia
(RTTNews) - Agios Pharmaceuticals, Inc. (AGIO) shares climbed 19.97%, closing at $29.50, up $4.91, after the U.S. Food and Drug Administration approved AQVESME (mitapivat) as an oral treatment for ane...
AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label
Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.
Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat
Shares of Agios Pharmaceuticals surged nearly 15% in premarket trading on Wednesday after the US Food and Drug Administration approved an expanded use of its drug mitapivat, strengthening investor opt...
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemia Treatment
Agios (AGIO) Surges 12% Following FDA Approval of New Thalassemia Treatment
Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
Shares of Agios Pharmaceuticals jumped nearly 12% premarket on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder...
Agios Pharmaceuticals (AGIO) Secures FDA Approval for AQVESME
Agios Pharmaceuticals (AGIO) Secures FDA Approval for AQVESME
FDA Approves Agios Pharmaceuticals' AQVESME (AGIO) for Thalassemia Treatment
FDA Approves Agios Pharmaceuticals' AQVESME (AGIO) for Thalassemia Treatment
FDA Approves Agios' AQVESME For Treatment Of Anemia In Alpha- And Beta-Thalassemia
(RTTNews) - Agios Pharmaceuticals Inc. (AGIO) announced that the U.S. Food and Drug Administration has approved AQVESME (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of anemia...
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi...
U.S. FDA Approves Agios' AQVESME™ (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemi...